{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'LIST OF FIGURES', 'Figure 1: Ravulizumab Every 8 Weeks Dosage Regimen Versus Eculizumab Every', '2 Weeks Dosage Regimen', '28', 'Figure 2: PK/PD/ADA Sampling for Clinical Deterioration', '53', 'Page 14 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '1.', 'PROTOCOL SUMMARY', '1.1.', 'Synopsis', 'Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study', 'to Evaluate the Safety and Efficacy of Ravulizumab in', 'Complement-Inhibitor-Na\u00efve Adult Patients With Generalized Myasthenia', 'Gravis', 'Short Title: Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia', 'Gravis', 'Rationale: Ravulizumab (ALXN1210) was engineered from eculizumab (h5G1.1-mAb)', 'humanized monoclonal antibody that specifically binds with high affinity to the human terminal', 'complement component (C5), inhibiting C5 enzymatic cleavage and thereby preventing the', 'generation of the proinflammatory/prothrombotic complement activation products, C5a, and the', 'cytolytic and proinflammatory/prothrombotic membrane attack complex, C5b-9, which are', 'responsible for the antibody-mediated destruction of the neuromuscular junction (NMJ), loss of', 'acetylcholine receptors, and failure of neuromuscular transmission associated with generalized', 'myasthenia gravis (gMG). Eculizumab is approved for the treatment of gMG, paroxysmal', 'nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome in many countries', 'worldwide, including Japan, the USA, and countries in the European Union under the trade name', 'Soliris', 'Ravulizumab preserves immediate and complete C5 inhibition while providing sustained', 'complement inhibition throughout a prolonged dosing interval; it was specifically designed (and', 'has subsequently been proven) to have an increased half-life relative to eculizumab. Therefore,', 'ravulizumab requires less frequent (once every 8 weeks [q8w]) infusions than eculizumab (once', 'every 2 weeks [q2w] infusions). Given that gMG is a chronic disease with a significant treatment', 'burden, the relative convenience of the ravulizumab dosing regimen may increase patient', 'satisfaction and treatment adherence, and ultimately, lead to improved health outcomes.', 'Ravulizumab was designed based on comprehensive modelling and simulation analyses to', 'maintain efficacious concentrations across an extended dosing interval. The enhanced', 'pharmacokinetic (PK)/pharmacodynamic profile of ravulizumab, with fewer PK troughs than', 'eculizumab, has the potential to improve therapeutic efficacy while maintaining a safety profile', 'similar to that of eculizumab. Furthermore, the q8w dosing regimen minimizes the risk of', 'incomplete complement inhibition.', 'Page 15 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Study ALXN1210-MG-306 Objectives and Enppoints', 'Objectives', 'Enppoints', 'Primary', 'To assess the efficacy of ravulizumab compared with', 'Change from Baseline in MG-ADL total score at', 'placebo in the treatment of gMG based on the', 'Week 26 of the Randomized-Controlled Period.', 'improvement in the Myasthenia Gravis-Activities of', 'Daily Living (MG-ADL) profile.', 'Secondary', 'To assess the efficacy of ravulizumab compared', 'Change from Baseline in QMG total score at', 'with placebo in the treatment of gMG based on', 'Week 26.', 'the improvement in the Quantitative Myasthenia', 'Gravis (QMG) total score.', 'To assess the efficacy of ravulizumab compared', 'Change from Baseline in the Revised', 'with placebo in the treatment of gMG based on', '15-Component Myasthenia Gravis Quality of Life', 'the improvement in quality of life measures.', '(MG-QOL15r) score at Week 26.', 'Change from Baseline in Neuro-QOL Fatigue', 'score at Week 26.', 'To assess the efficacy of ravulizumab compared', 'Improvement of at least 3 points in the MG-ADL', 'with placebo in the treatment of gMG based on', 'total score from Baseline at Week 26.', 'other efficacy endpoints.', 'Improvement of at least 5 points in the QMG total', 'score from Baseline at Week 26.', 'Exploratory', 'To assess the efficacy of ravulizumab in the', 'Change from Baseline in the Myasthenia Gravis', 'treatment of gMG based on other efficacy', 'Composite (MGC) score at Week 26.', 'endpoints throughout the study.', 'Myasthenia Gravis Foundation of America', '(MGFA) Post-Intervention Status (PIS) at', 'Week 26.', 'Change from Baseline in Euro Quality of Life', '(EQ-5D-5L) at Week 26.', 'Change from baseline in MG-ADL subcomponent', 'scores (bulbar, limbs, respiratory, and ocular) at', 'Week 26.', 'Change from baseline in QMG subcomponent', 'scores (bulbar, limbs, respiratory, and ocular) at', 'Week 26.', 'Incidence of hospitalizations/MG-related', 'hospitalizations.', 'Incidence of Clinical Deterioration/MG crisis.', 'PK/PD/Immunogenicity', 'To evaluate the PK/PD and immunogenicity of', 'Change in serum ravulizumab concentration over', 'ravulizumab in the treatment of gMG throughout', 'time.', 'the study.', 'Change in serum free C5 concentration over time.', 'Incidence of treatment-emergent antidrug', 'antibodies over time.', 'Safety', 'To characterize the overall safety of ravulizumab in', 'Incidence of adverse events and serious adverse', 'the treatment of gMG.', 'events over time.', 'Changes from Baseline in vital signs and', 'laboratory assessments.', 'The above endpoints will be evaluated over time throughout the study.', 'Page 16 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}